Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) EPS (Weighted Average and Diluted) (2016 - 2025)

Macrogenics (MGNX) has disclosed EPS (Weighted Average and Diluted) for 12 consecutive years, with -$0.22 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 8.33% to -$0.22 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.18, a 10.28% decrease, with the full-year FY2025 number at -$1.18, down 10.28% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.22 for Q4 2025 at Macrogenics, down from $0.26 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.92 in Q2 2023 to a low of -$1.08 in Q1 2022.
  • A 5-year average of -$0.39 and a median of -$0.63 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 2195.86% in 2021, then soared 237.31% in 2023.
  • Macrogenics' EPS (Weighted Average and Diluted) stood at -$0.95 in 2021, then soared by 122.11% to $0.21 in 2022, then crashed by 457.14% to -$0.75 in 2023, then skyrocketed by 68.0% to -$0.24 in 2024, then increased by 8.33% to -$0.22 in 2025.
  • Per Business Quant, the three most recent readings for MGNX's EPS (Weighted Average and Diluted) are -$0.22 (Q4 2025), $0.26 (Q3 2025), and -$0.57 (Q2 2025).